Skip to main content

Table 5 Risk factors tested for association with 5-FU- and capecitabine-associated cardiotoxicity

From: Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study

Variable

Patients with cardiotoxicity (n = 161)

Patients without cardiotoxicity (n = 366)

P

Chemotherapy

 5-Fluorouracil

49 (30.4)

147 (40.2)

0.033

 Capecitabine

112 (69.6)

219 (59.8)

 

Chemotherapy cycle

 1–4

53 (32.9)

143 (39.1)

0.386

 5–9

91 (56.5)

177 (48.4)

 

 ≥ 9

9 (5.6)

26 (7.1)

 

 UK

8 (5.0)

20 (5.5)

 

Concurrent radiotherapy

 Yes

6 (3.7)

16 (4.4)

0.733

 No

155 (96.3)

350 (95.6)

 

Sex

 Male

108 (67.1)

240 65.6)

0.737

 Female

53 (32.9)

126 (34.4)

 

Age, years

 ≤ 29

4 (2.5)

6 (1.6)

0.257

 30~

9 (5.6)

23 (6.3)

 

 40~

33 (20.5)

79 (21.6)

 

 50~

40 (24.8)

110 (30.1)

 

 60~

54 (33.5)

124 (33.9)

 

 70~

19 (11.8)

23 (6.3)

 

 80~

2 (1.2)

1 (0.3)

 

Pre-existing disease

 Hypertension

  Yes

44 (27.3)

62 (16.9)

0.006

  No

117 (72.7)

304 83.1)

 

 Diabetes

  Yes

11 (6.8)

18 (4.9)

0.375

  No

150 (93.2)

348 (95.1)

 

 Cardiac disease

  Yes

9 (5.6)

4 (1.1)

0.004

  No

152 (94.4)

362 (98.9)

 

 Hyperlipidemia

  Yes

2 (1.2)

2 (0.5)

0.762

  No

159 (98.8)

364 (99.5)

 

Surgical history

 Yes

129 (80.1)

286 (78.1)

0.608

 No

32 (19.9)

80 (21.9)

 

Treatment history

 Chemotherapy

  Yes

33 (20.5)

85 (23.2)

0.521

  No

128 (79.5)

281 (76.8)

 

 Radiotherapy

  Yes

9 (5.6)

23 (6.3)

0.759

  No

152 (94.4)

343 (93.7)

 

 Chemotherapy and radiotherapy

  Yes

7 (4.3)

19 (5.2)

0.808

  No

154 (95.7)

347 (94.8)